A cardiologist and physician-scientist, Aarif Khakoo is responsible for the discovery and advancement of Amgen’s Metabolic Disorders pipeline including cardiovascular disease, obesity, diabetes, bone disease, and chronic kidney disease. Aarif’s research organization is focused on leveraging findings from common and rare variant human genetics in an effort to increase the speed and success rate of drug development in complex cardiovascular and metabolic diseases.
Aarif joined Amgen in 2011, and led the Cardiovascular Discovery Research Program in the areas of heart failure, atherosclerosis, pulmonary hypertension and other human cardiovascular diseases. Aarif was later named the company’s San Francisco site head responsible for Amgen’s largest research site outside of its headquarters in Thousand Oaks, CA.
Aarif received his MD and his MBA from Columbia University, and completed his internal medicine residency and a fellowship in cardiovascular medicine at the Johns Hopkins University School of Medicine. In 2005, Aarif joined the faculty at University of Texas MD Anderson Cancer Center, where he spent six years heading an NIH-funded laboratory whose research focus was to understand the cellular mechanisms of cardiac toxicity due to novel, molecularly targeted anti-cancer therapeutics. In addition to his research activities at Amgen, Aarif continues to practice cardiovascular medicine on a consultative basis at the Palo Alto VA Medical Center as an Adjunct Associate Professor at Stanford University. He serves on the board of the Silicon Valley Leadership Group.